HEALTH PROFESSIONAL · SOURCE READING

Immune checkpoint inhibitors with or without chemotherapy

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC (First-Line Therapy)

Pembrolizumab is a humanized monoclonal antibody that inhibits the interaction between the programmed death protein 1 (PD-1) coinhibitory immune checkpoint expressed on tumor cells and infiltrating immune cells and its ligands, PD-L1 and PD-L2.[89]

Source links and citations

Continue within this section

Pembrolizumab plus chemotherapy →Pembrolizumab alone →Cemiplimab-rwlc plus chemotherapy →Cemiplimab-rwlc alone →Tremelimumab →Atezolizumab alone →Atezolizumab plus chemotherapy →Atezolizumab plus bevacizumab plus chemotherapy →Nivolumab plus ipilimumab →

Publication references

Read the original reference and check its publication notices.

PubMed 27718847 · Original source

Preserved source evidence · Not medical advice